Day 3 at the 2017 annual meeting of the American Society of Clinical Oncology touched on immunotherapy combinations and the promise of several novel immunotherapies, including anti-IDO1 checkpoint blockade and a personalized, patient-specific vaccine. Other measures of immunotherapy’s effectiveness, such as patient quality of life, were also discussed. Below are some of the most important findings that were revealed today:
Multiple Tumor Types:
Head and Neck Cancer:
Melanoma / Skin Cancers:
Stomach & Gastrointestinal Cancer:
ASCO17: Day 1 Immunotherapy Highlights
Read Previous Article
ASCO17: Day 3 Immunotherapy Highlights
Read Next Article
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
CRI Lloyd J. Old STAR Tal Danino is exploring how to engineer bacteria to help our bodies better fight cancer.
Meet three promising young scientists changing the face of immuno-oncology: Ryan K. Alexander, Ph.D., of Boston Children’s Hospital; Nelson M. LaMarche, Ph.D., of the Icahn School of Medicine at Mount Sinai; and Christopher B. Medina, Ph.D., of Emory University.